Is GUTS or PYXS more profitable?

Pyxis Oncology's return on equity of -215.23% beat Fractyl Health's return on equity. Company Net Margins Return on Equity Return on Assets Fractyl Health N/A -1,362.10% -84.89% Pyxis Oncology N/A -215.23% -112.19%

Does the media prefer GUTS or PYXS?

In the previous week, Fractyl Health had 13 more articles in the media than Pyxis Oncology. MarketBeat recorded 18 mentions for Fractyl Health and 5 mentions for Pyxis Oncology. Pyxis Oncology's average media sentiment score of 0.82 beat Fractyl Health's score of -0.10 indicating that Pyxis Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fractyl Health 0 Very Positive mention(s) 0 Positive mention(s) 16 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Pyxis Oncology 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PYXS or PHAR?

In the previous week, Pyxis Oncology had 3 more articles in the media than Pharming Group. MarketBeat recorded 5 mentions for Pyxis Oncology and 2 mentions for Pharming Group. Pyxis Oncology's average media sentiment score of 0.82 beat Pharming Group's score of 0.40 indicating that Pyxis Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pyxis Oncology 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pharming Group 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is PYXS or IMMX more profitable?

Immix Biopharma's return on equity of -38.44% beat Pyxis Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Pyxis Oncology N/A -215.23% -112.19% Immix Biopharma N/A -38.44% -34.72%

Does the media refer more to PYXS or IMMX?

In the previous week, Pyxis Oncology had 2 more articles in the media than Immix Biopharma. MarketBeat recorded 5 mentions for Pyxis Oncology and 3 mentions for Immix Biopharma. Pyxis Oncology's average media sentiment score of 0.82 beat Immix Biopharma's score of 0.41 indicating that Pyxis Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pyxis Oncology 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immix Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is PYXS or NVCT more profitable?

Nuvectis Pharma's return on equity of -184.25% beat Pyxis Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Pyxis Oncology N/A -215.23% -112.19% Nuvectis Pharma N/A -184.25% -105.24%

Does the media favor PYXS or NVCT?

In the previous week, Pyxis Oncology had 1 more articles in the media than Nuvectis Pharma. MarketBeat recorded 5 mentions for Pyxis Oncology and 4 mentions for Nuvectis Pharma. Pyxis Oncology's average media sentiment score of 0.82 beat Nuvectis Pharma's score of 0.00 indicating that Pyxis Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pyxis Oncology 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nuvectis Pharma 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, PYXS or MDXG?

MiMedx Group has higher revenue and earnings than Pyxis Oncology. Pyxis Oncology is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pyxis Oncology $11.04M 15.34 -$79.62M -$1.41 N/A MiMedx Group $418.63M 1.63 $48.58M $0.04 116.75

Does the media refer more to PYXS or MDXG?

In the previous week, MiMedx Group had 1 more articles in the media than Pyxis Oncology. MarketBeat recorded 6 mentions for MiMedx Group and 5 mentions for Pyxis Oncology. Pyxis Oncology's average media sentiment score of 0.82 beat MiMedx Group's score of 0.20 indicating that Pyxis Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pyxis Oncology 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MiMedx Group 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Pyxis Oncology (PYXS) Competitors

$2.03 +0.04 (+2.01%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$2.03 0.00 (0.00%)

As of 10/9/2026 07:30 PM Eastern

Compare

PYXS vs. GUTS, PHAR, IMMX, NVCT, and MDXG

Should you buy Pyxis Oncology stock or one of its competitors? Pyxis Oncology's main competitors and comparable companies include Fractyl Health (GUTS), Pharming Group (PHAR), Immix Biopharma (IMMX), Nuvectis Pharma (NVCT), and MiMedx Group (MDXG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Pyxis Oncology compare to Fractyl Health?

Fractyl Health (NASDAQ:GUTS) and Pyxis Oncology (NASDAQ:PYXS) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

In the previous week, Fractyl Health had 13 more articles in the media than Pyxis Oncology. MarketBeat recorded 18 mentions for Fractyl Health and 5 mentions for Pyxis Oncology. Pyxis Oncology's average media sentiment score of 0.82 beat Fractyl Health's score of -0.10 indicating that Pyxis Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fractyl Health	0 Very Positive mention(s)	0 Positive mention(s)	16 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Pyxis Oncology	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Fractyl Health has a beta of 2.42, suggesting that its share price is 142% more volatile than the broader market. Comparatively, Pyxis Oncology has a beta of 1.37, suggesting that its share price is 37% more volatile than the broader market.

Pyxis Oncology's return on equity of -215.23% beat Fractyl Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fractyl Health	N/A	-1,362.10%	-84.89%
Pyxis Oncology	N/A	-215.23%	-112.19%

Fractyl Health currently has a consensus price target of $66.00, indicating a potential upside of 1,393.21%. Pyxis Oncology has a consensus price target of $8.75, indicating a potential upside of 331.03%. Given Fractyl Health's higher possible upside, research analysts clearly believe Fractyl Health is more favorable than Pyxis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fractyl Health	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Pyxis Oncology has higher revenue and earnings than Fractyl Health. Fractyl Health is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fractyl Health	$90K	651.21	-$140.95M	-$0.88	N/A
Pyxis Oncology	$11.04M	15.34	-$79.62M	-$1.41	N/A

39.1% of Pyxis Oncology shares are held by institutional investors. 8.4% of Fractyl Health shares are held by insiders. Comparatively, 5.7% of Pyxis Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Fractyl Health beats Pyxis Oncology on 8 of the 15 factors compared between the two stocks.

How does Pyxis Oncology compare to Pharming Group?

Pyxis Oncology (NASDAQ:PYXS) and Pharming Group (NASDAQ:PHAR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment.

Pyxis Oncology presently has a consensus price target of $8.75, indicating a potential upside of 331.03%. Pharming Group has a consensus price target of $38.67, indicating a potential upside of 294.96%. Given Pyxis Oncology's stronger consensus rating and higher probable upside, equities research analysts plainly believe Pyxis Oncology is more favorable than Pharming Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Pharming Group	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Pyxis Oncology has a beta of 1.37, indicating that its stock price is 37% more volatile than the broader market. Comparatively, Pharming Group has a beta of -0.05, indicating that its stock price is 105% less volatile than the broader market.

In the previous week, Pyxis Oncology had 3 more articles in the media than Pharming Group. MarketBeat recorded 5 mentions for Pyxis Oncology and 2 mentions for Pharming Group. Pyxis Oncology's average media sentiment score of 0.82 beat Pharming Group's score of 0.40 indicating that Pyxis Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pyxis Oncology	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pharming Group	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pharming Group has a net margin of 2.51% compared to Pyxis Oncology's net margin of 0.00%. Pharming Group's return on equity of 3.40% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pyxis Oncology	N/A	-215.23%	-112.19%
Pharming Group	2.51%	3.40%	1.90%

39.1% of Pyxis Oncology shares are owned by institutional investors. Comparatively, 0.0% of Pharming Group shares are owned by institutional investors. 5.7% of Pyxis Oncology shares are owned by insiders. Comparatively, 2.1% of Pharming Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Pharming Group has higher revenue and earnings than Pyxis Oncology. Pyxis Oncology is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pyxis Oncology	$11.04M	15.34	-$79.62M	-$1.41	N/A
Pharming Group	$366.48M	1.89	$2.85M	$0.12	81.58

Summary

Pyxis Oncology beats Pharming Group on 9 of the 16 factors compared between the two stocks.

How does Pyxis Oncology compare to Immix Biopharma?

Pyxis Oncology (NASDAQ:PYXS) and Immix Biopharma (NASDAQ:IMMX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

39.1% of Pyxis Oncology shares are owned by institutional investors. Comparatively, 11.3% of Immix Biopharma shares are owned by institutional investors. 5.7% of Pyxis Oncology shares are owned by company insiders. Comparatively, 30.3% of Immix Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Pyxis Oncology has a beta of 1.37, indicating that its share price is 37% more volatile than the broader market. Comparatively, Immix Biopharma has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market.

In the previous week, Pyxis Oncology had 2 more articles in the media than Immix Biopharma. MarketBeat recorded 5 mentions for Pyxis Oncology and 3 mentions for Immix Biopharma. Pyxis Oncology's average media sentiment score of 0.82 beat Immix Biopharma's score of 0.41 indicating that Pyxis Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pyxis Oncology	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immix Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Immix Biopharma's return on equity of -38.44% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pyxis Oncology	N/A	-215.23%	-112.19%
Immix Biopharma	N/A	-38.44%	-34.72%

Pyxis Oncology currently has a consensus target price of $8.75, indicating a potential upside of 331.03%. Immix Biopharma has a consensus target price of $24.14, indicating a potential upside of 155.21%. Given Pyxis Oncology's higher probable upside, research analysts clearly believe Pyxis Oncology is more favorable than Immix Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Immix Biopharma	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

Immix Biopharma has lower revenue, but higher earnings than Pyxis Oncology. Immix Biopharma is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pyxis Oncology	$11.04M	15.34	-$79.62M	-$1.41	N/A
Immix Biopharma	N/A	N/A	-$29.44M	-$0.88	N/A

Summary

Pyxis Oncology beats Immix Biopharma on 7 of the 13 factors compared between the two stocks.

How does Pyxis Oncology compare to Nuvectis Pharma?

Pyxis Oncology (NASDAQ:PYXS) and Nuvectis Pharma (NASDAQ:NVCT) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, media sentiment, analyst recommendations, dividends, earnings and institutional ownership.

Pyxis Oncology has a beta of 1.37, suggesting that its stock price is 37% more volatile than the broader market. Comparatively, Nuvectis Pharma has a beta of -0.24, suggesting that its stock price is 124% less volatile than the broader market.

Nuvectis Pharma's return on equity of -184.25% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pyxis Oncology	N/A	-215.23%	-112.19%
Nuvectis Pharma	N/A	-184.25%	-105.24%

39.1% of Pyxis Oncology shares are held by institutional investors. Comparatively, 96.8% of Nuvectis Pharma shares are held by institutional investors. 5.7% of Pyxis Oncology shares are held by insiders. Comparatively, 28.5% of Nuvectis Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Nuvectis Pharma has lower revenue, but higher earnings than Pyxis Oncology. Nuvectis Pharma is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pyxis Oncology	$11.04M	15.34	-$79.62M	-$1.41	N/A
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A

In the previous week, Pyxis Oncology had 1 more articles in the media than Nuvectis Pharma. MarketBeat recorded 5 mentions for Pyxis Oncology and 4 mentions for Nuvectis Pharma. Pyxis Oncology's average media sentiment score of 0.82 beat Nuvectis Pharma's score of 0.00 indicating that Pyxis Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pyxis Oncology	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nuvectis Pharma	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pyxis Oncology presently has a consensus price target of $8.75, indicating a potential upside of 331.03%. Nuvectis Pharma has a consensus price target of $36.25, indicating a potential upside of 71.64%. Given Pyxis Oncology's higher possible upside, research analysts clearly believe Pyxis Oncology is more favorable than Nuvectis Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Summary

Nuvectis Pharma beats Pyxis Oncology on 8 of the 15 factors compared between the two stocks.

How does Pyxis Oncology compare to MiMedx Group?

Pyxis Oncology (NASDAQ:PYXS) and MiMedx Group (NASDAQ:MDXG) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

In the previous week, MiMedx Group had 1 more articles in the media than Pyxis Oncology. MarketBeat recorded 6 mentions for MiMedx Group and 5 mentions for Pyxis Oncology. Pyxis Oncology's average media sentiment score of 0.82 beat MiMedx Group's score of 0.20 indicating that Pyxis Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pyxis Oncology	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MiMedx Group	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pyxis Oncology has a beta of 1.37, suggesting that its stock price is 37% more volatile than the broader market. Comparatively, MiMedx Group has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market.

MiMedx Group has a net margin of 1.76% compared to Pyxis Oncology's net margin of 0.00%. MiMedx Group's return on equity of 12.09% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pyxis Oncology	N/A	-215.23%	-112.19%
MiMedx Group	1.76%	12.09%	9.22%

Pyxis Oncology currently has a consensus target price of $8.75, indicating a potential upside of 331.03%. MiMedx Group has a consensus target price of $8.57, indicating a potential upside of 83.54%. Given Pyxis Oncology's higher probable upside, analysts plainly believe Pyxis Oncology is more favorable than MiMedx Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

39.1% of Pyxis Oncology shares are held by institutional investors. Comparatively, 79.2% of MiMedx Group shares are held by institutional investors. 5.7% of Pyxis Oncology shares are held by insiders. Comparatively, 2.5% of MiMedx Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

MiMedx Group has higher revenue and earnings than Pyxis Oncology. Pyxis Oncology is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pyxis Oncology	$11.04M	15.34	-$79.62M	-$1.41	N/A
MiMedx Group	$418.63M	1.63	$48.58M	$0.04	116.75

Summary

MiMedx Group beats Pyxis Oncology on 10 of the 16 factors compared between the two stocks.

Get Pyxis Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PYXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PYXS vs. The Competition

Export

Metric	Pyxis Oncology	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$169.32M	$3.85B	$7.16B	$13.21B
Dividend Yield	N/A	3.66%	2.53%	16.37%
P/E Ratio	N/A	13.62	275.30	26.16
Price / Sales	12.22	1,234.34	635.99	108.09
Price / Cash	N/A	116.56	76.38	53.09
Price / Book	2.36	17.17	11.22	6.33
Net Income	-$79.62M	-$22.69M	$3.50B	$382.15M
7 Day Performance	-5.14%	-1.34%	-0.89%	-1.40%
1 Month Performance	-37.92%	-8.45%	-4.42%	-3.47%
1 Year Performance	-45.06%	14.02%	7.03%	1.18%

Pyxis Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count
PYXS Pyxis Oncology	2.6105 of 5 stars	$2.03 +2.0%	$8.75 +331.0%	-47.0%	$169.32M	$13.86M	N/A	56
GUTS Fractyl Health	2.7401 of 5 stars	$4.43 -2.9%	$66.00 +1,389.8%	-73.7%	$705.65M	$90K	N/A	73
PHAR Pharming Group	4.1869 of 5 stars	$9.88 +0.8%	$38.67 +291.4%	-32.9%	$699.31M	$376.13M	82.33	407
IMMX Immix Biopharma	2.8127 of 5 stars	$9.71 -4.1%	$24.14 +148.6%	+266.7%	$695.44M	N/A	N/A	21
NVCT Nuvectis Pharma	2.293 of 5 stars	$20.60 -3.7%	$36.25 +76.0%	+251.4%	$672.22M	N/A	N/A	13

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PYXS) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pyxis Oncology (PYXS) Competitors

PYXS vs. GUTS, PHAR, IMMX, NVCT, and MDXG

How does Pyxis Oncology compare to Fractyl Health?

Summary

How does Pyxis Oncology compare to Pharming Group?

Summary

How does Pyxis Oncology compare to Immix Biopharma?

Summary

How does Pyxis Oncology compare to Nuvectis Pharma?

Summary

How does Pyxis Oncology compare to MiMedx Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PYXS vs. The Competition

Pyxis Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pyxis Oncology (PYXS) Competitors

PYXS vs. GUTS, PHAR, IMMX, NVCT, and MDXG

How does Pyxis Oncology compare to Fractyl Health?

Does the media prefer GUTS or PYXS?

Which has more risk and volatility, GUTS or PYXS?

Is GUTS or PYXS more profitable?

Do analysts rate GUTS or PYXS?

Which has better valuation and earnings, GUTS or PYXS?

Do insiders & institutionals believe in GUTS or PYXS?

Summary

How does Pyxis Oncology compare to Pharming Group?

Do analysts rate PYXS or PHAR?

Which has more volatility and risk, PYXS or PHAR?

Does the media refer more to PYXS or PHAR?

Is PYXS or PHAR more profitable?

Do insiders and institutionals hold more shares of PYXS or PHAR?

Which has better valuation and earnings, PYXS or PHAR?

Summary

How does Pyxis Oncology compare to Immix Biopharma?

Do insiders & institutionals hold more shares of PYXS or IMMX?

Which has more volatility & risk, PYXS or IMMX?

Does the media refer more to PYXS or IMMX?

Is PYXS or IMMX more profitable?

Do analysts rate PYXS or IMMX?

Which has higher earnings & valuation, PYXS or IMMX?

Summary

How does Pyxis Oncology compare to Nuvectis Pharma?

Which has more risk & volatility, PYXS or NVCT?

Is PYXS or NVCT more profitable?

Do institutionals and insiders hold more shares of PYXS or NVCT?

Which has higher valuation and earnings, PYXS or NVCT?

Does the media favor PYXS or NVCT?

Do analysts prefer PYXS or NVCT?

Summary

How does Pyxis Oncology compare to MiMedx Group?

Does the media refer more to PYXS or MDXG?

Which has more risk and volatility, PYXS or MDXG?

Is PYXS or MDXG more profitable?

Do analysts prefer PYXS or MDXG?

Do institutionals & insiders hold more shares of PYXS or MDXG?

Which has preferable earnings & valuation, PYXS or MDXG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PYXS vs. The Competition

Pyxis Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools